By Clinical Research News Staff

January 31, 2025 | The Best of Show People’s Choice Award Finalists are now announced for next week’s 2025 Summit for Clinical Ops Executives (SCOPE). With a record number of finalists, this promises to be the most competitive year yet for clinical new products.

Clinical Research News’ Best of Show Awards program recognizes the best new products in the clinical research space. Any company exhibiting at SCOPE was invited to enter a new product and the winners are chosen during public voting on site in Orlando. Please note, selection is not based on level of sponsorship or exhibit participation.

All of the finalists will be recognized at their booths in the Exhibit Hall and attendees are encouraged to explore the novel technologies and solutions firsthand to identify exceptional innovation in technologies used by life science professionals, voting on the most impactful new products of the year.

Winners will be chosen by the SCOPE community voting during the event. Voting links will be available at finalists’ booths and throughout the event. Voting will open when the exhibit hall opens on Tuesday, February 4 at 9:50 am. Voting will close at noon on Wednesday, February 5. Winners will be announced at 2 pm during the Coffee and Networking break in the Exhibit Hall on Wednesday and during the Wednesday afternoon plenary session.

New products are finalists from the following companies: 1nHealth, Almac Clinical Technologies, Anju Software, BEKhealth, Biorce, Cencora PharmaLex, Citeline, CluePoints, Credible Planning, Crucial Data Solutions, Cyntegrity, Embleema, EmVenio Research, Everyday Health Group, EvidentIQ, Exostar, GlobalData, Greenphire, H1, Havas Faze, Image Analysis Group, Inspire, IQVIA, Keiji AI, LexisNexis Risk Solutions, MaxisIT, Medable, Medidata, Milliman IntelliScript, Nurocor, Phastar, Phesi, Praxis, Replior, Saama, ScienceMedia, Scout, Signant Health, Sitero, Slope, StudyKIK, Synterex, Tasso, Trial By Fire Solutions, Trialbee, TruTechnologies, Truveta, Univo IRB, Veeva Systems, Veridix AI, VIDA, Voiant, WCG Clinical, YPrime, and Yuna.

Read about each company’s new product in their own words below.

1nHealth | 1nHealth: We Own Enrollment | Booth 616  https://1nhealth.com/  

Brief Product Description & Technical Specifications:

1nHealth is dedicated to revolutionizing patient enrollment for clinical trials. With over 30,000 patients enrolled across more than 100 studies, 1nHealth helps study sponsors and clinical research organizations overcome enrollment challenges, connect representative patient populations to clinical studies, and improve trial outcomes. More than 700 research sites use 1nData’s cutting-edge enrollment tracking and communication technology, allowing them to connect quickly with patients, access real-time study data, and make well-informed decisions at every level. 1nHealth’s commitment to accelerating enrollment with the patient at the center ensures that every trial supported is positioned for success and advances human health. 

Almac Clinical Technologies | Your Research, a member of the ALMAC Group | Booth 302  https://yourresearch.com 

Brief Product Description & Technical Specifications: 

Your Research, a member of the ALMAC Group, is an innovative cloud-based SaaS platform that unifies workflows and redefines eCOA and CTMS solutions for clinical researchers, pharmaceutical companies, CROs, and trial sites. Designed with a core focus on patient centricity, our modular solutions seamlessly align with every stage of the participant journey, enabling an unmatched clinical trial experience.  

Key Features:  

1. Data Management - Real-time data capture with secure, centralized storage. o Advanced analytics and fully customizable dashboards for actionable insights.  

2. Seamless Integration - API compatibility with EHR/EMR systems, wearable devices, and trial software. - Adherence to global standards, including HL7 and FHIR.  

3. Exceptional User Experience - A multilingual, intuitive interface tailored for patients and clinicians. - Mobile-first, responsive design ensures accessibility on iOS, Android, and browsers.  

4. Smart Automation - Automated patient and clinician scheduling for streamlined coordination. - Automated reminders, notifications, and optimized resource allocation.  

5. Compliance and Security - Full adherence to HIPAA, GDPR, 21 CFR Part 11, GCP, ISO 27001, and ICH E6 (R2). With innovation at its core, Your Research delivers a superior user experience by blending cutting-edge technology with intuitive workflows. Our patient-centric approach ensures each modular solution is purpose-built to enhance engagement, simplify processes, and drive better outcomes.  

Scalable and Supported Globally:  

• Fully cloud-managed, requiring no on-site setup.  

• 24/7 technical support and dedicated account managers.  

• Configurable for regional and multinational trials of any complexity. 

Anju Software | TA Scan v1.7.8.3 | Booth 1016  https://www.anjusoftware.com/ta-scan-data-science/  

Brief Product Description & Technical Specifications. Be sure to specify what is new in this release: 

TA Scan is a cloud-based clinical and commercial business intelligence tool that aggregates and connects a broad range of global clinically relevant data sources. Clinical trials, presentations, publications, and many other data sources from the public domain are semantically linked into a single intuitive database. Our high-quality data and built-in advanced analytics provide an accurate, comprehensive view of global R&D activity, allowing users to make more informed decisions around their study designs, feasibility, site identification, investigator/KOL identification, and management strategies. In the past year, TA Scan expanded its core feature for clinical operations teams. TA Scan’s new Trial Feasibility Flex simplifies the highly complex process of clinical trial feasibility, thereby adding strategic and operational value. While keeping TA Scan’s high-quality data and powerful functionalities, the Trial Feasibility Flex allows more customizable manual inputs, enabling highly precise enrollment projections tailored to the users’ trial design. Through the simulation, users can assess the impact of a wide range of variables – such as country selection, preferred site lists, country-level patient distribution, regulatory delay, anticipated recruitment rate, and other trial parameters – on clinical outcomes. On top of predictive enrollment scenarios, country-level trial timings, and competitive insights, Trial Feasibility Flex provides feedback on sponsors’ preferred site list, by assessing specific trial criteria and sites’ capacity in the current competitive landscape. Moreover, it provides alternative sites with capacity to recruit. The insights generated help match reality with expectation and generate the actionable insights needed to optimize country and site selection, supporting confident and efficient trial planning. 

 BEKhealth | BEKplatform | Booth 1224  https://www.bekhealth.com 

Brief Product Description & Technical Specifications:

We released version 4.18 of the BEK platform on May 18th 2024. This was a major release that turned on our cancer QA screening and staging detection module in our natural language processing pipeline. Following this release we are able to extract tumor staging information from free text notes which enables our patient matching to work across a broad range of cancer studies that were previously not possible for the BEK platform to support. 

Biorce | Jarvis V2 | Booth 541  https://www.biorce.com/home 

Brief Product Description & Technical Specifications:

Product Description Jarvis is the first Clinical Trial AI Assistant designed to revolutionize the planning, execution, and optimization of clinical studies. By leveraging a vast database of over 500,000 studies, Jarvis offers intelligent solutions for protocol design, feasibility analysis, site selection, and patient recruitment. Its advanced AI capabilities streamline inclusion/exclusion criteria, sample size optimization, and dosage prediction, minimizing the costly and time-intensive protocol amendments that affect 57% of trials. Jarvis empowers users with actionable insights by consolidating and analyzing data at unprecedented speed, performing hundreds of hours of research in seconds. Its intuitive interface facilitates dynamic interactions, such as providing demographic and population insights, intervention comparisons, endpoint measures, and efficacy results. Whether it’s doctors seeking patient-trial matches, researchers analyzing past methodologies, or industry stakeholders optimizing study designs, Jarvis enhances efficiency, reduces errors, and accelerates timelines. It also empowers patients by simplifying access to relevant clinical trials, reducing their burden, and expanding participation opportunities. Technical Specifications • AI Capabilities: Advanced search, trend identification, and comparative analysis across extensive clinical trial databases. • Optimization Tools: Algorithms for refining inclusion/exclusion criteria, sample size, and drug dosage predictions. • Feasibility Analysis: Site workload assessments and patient availability predictions to aid in site selection. • Data Insights: Provides patient demographics, intervention details, outcome measures, and efficacy results. • Integration: Ability to integrate with existing clinical research workflows to improve decision-making efficiency. • Time Savings: Condenses 100+ hours of research into seconds for rapid protocol development 

Cencora PharmaLex | PhlexTMF v21.7 | Booth 132  https://www.phlexglobal.com/phlextmf-v21 

Brief Product Description & Technical Specifications: 

PhlexTMF v21 is a purpose-built eTMF solution with next-generation artificial intelligence that helps ensure clinical documents are “right-first-time” at the critical document upload step. Organizations can utilize PhlexTMF v21 to significantly reduce TMF document misfiles and metadata errors – improving TMF quality, completeness, and timeliness, while freeing busy study teams from time-consuming queries and remediation effort. Documentation misfiles and metadata errors continue to severely impact TMF quality across our industry, increasing inspection risk and adding an avoidable QC burden on overwhelmed staff. Pre-trained on millions of TMF documents and embedding the cumulative guidance of hundreds of Phlexglobal’s (now part of Cencora PharmaLex) TMF experts, PhlexTMF v21 allows companies to prevent many of these critical problems before they occur – immediately improving TMF management and inspection-readiness. Every misfiled document can cascade into significant downstream impact and risk, since to an inspector the misfiled document does not officially exist and cannot be used in the eTMF to support the “story” of the trial. With TMF misfile rates approaching – and in some cases exceeding – 10% in some companies, PhlexTMF v21 helps prevent a single pebble from turning into an avalanche of risk. Unlike simple, first-generation TMF “bots” that require lengthy training on an organization’s own documents before delivering even limited value, Phlexglobal’s next-generation AI solution is ready to go on day one. Any life sciences organization, large or small, can obtain immediate value with the industry’s most complete and robust corpus of TMF document-handling algorithms. 

Citeline | Citeline SmartSolutions - version 1 | Booth 608  https://www.citeline.com/smartsolutions 

Brief Product Description & Technical Specifications:

Citeline SmartSolutions — Protocol SmartDesign and Investigator SmartSelect — give medical, clinical operations, and feasibility teams a competitive advantage by building more predictable trials and accelerating development timelines. It all starts with Citeline’s vast database of historic trial information in structured and unstructured forms. Protocol SmartDesign was developed with AI technology, categorizing data using logistic regression for primary endpoints and the deep learning model, BioBERT, for the inclusion and exclusion (I/E) criteria. Recommendations for endpoints and I/E are generated using the Claude 3/3.5 Sonnet large language model. Predictive enrollment rates and length of study are delivered via the machine learning models, CatBoost and Random Forest. Investigator SmartSelect allows researchers to generate a pool of protocol-specific investigators in minutes. With our proprietary algorithm — factoring in more than two dozen investigator and study properties in Citeline’s database of 590,000+ investigators as well as real-world claims, electronic health records, and epidemiology and payment data — they can identify the best countries, site allocations, and investigators for their trial. Each investigator is scored by the algorithm and ranked based on the target study criteria. 

Clindex | Clindex - 7.2 | Booth 630 https://www.clindex.com/

Brief Product Description & Technical Specifications:

The Clindex Site Feasibility feature is a newly developed tool within the Clindex eClinical platform, designed to transform site feasibility assessments into a fully digital, streamlined process. This feature allows sponsors to distribute study information, collect feasibility data, and evaluate site suitability—all within a unified system. Key functionalities include access control, a detailed audit trail, and robust reporting capabilities, ensuring compliance with regulatory standards like GCP and GDPR.

Core Features:

1. Digital Feasibility Questionnaires: Sites can complete online questionnaires, replacing traditional paper forms and spreadsheets.

2. Sponsor Evaluation and Site Selection: Sponsors can review site responses, evaluate their fit for the study, and invite selected sites to participate.

3. Integrated Workflow: Sites seamlessly transition from feasibility to activation, eliminating the need for duplicative data entry or system migrations.

4. Centralized Site Database: Sponsors can store and manage site feasibility data for reuse in future studies, reducing time and effort for subsequent trials.

5. Controlled Access and Audit Trail: Every action is logged, ensuring full traceability and compliance with regulatory requirements.

Technical Specifications:

• Platform Integration: Fully integrated into the Clindex platform, encompassing EDC, CTMS, and eTMF functionalities.

• Data Security: Encrypted data storage and role-based access controls to ensure confidentiality and compliance.

• Customizable Reporting: Generate real-time reports on site performance, questionnaire responses, and overall study feasibility metrics.

• Scalability: Suitable for sponsors conducting trials across multiple sites and studies. The Clindex Site Feasibility feature revolutionizes how sponsors and sites collaborate, enabling faster, more informed decision-making and delivering higher-quality outcomes for clinical trials.

CluePoints | Site Profile & Oversight Tool (SPOT) V1 | Booth 809  https://cluepoints.com/what-we-do/site-profile-oversight-tool-spot/  

Brief Product Description & Technical Specifications: 

The new Site Profile & Oversight Tool (SPOT) integrates data from a range of sources, including CTMS, EDC and Centralized Monitoring. It circumvents rigid SDR strategies, reduces unnecessary monitoring efforts and prioritizes resource allocation. SPOT quantifies site risk levels from centralized monitoring and estimates both a backlog and a forecast of CRA monitoring visit workload since the date of the last monitoring visit. An analytics landing zone enables the visualization of key data to drive actionable insights that inform adaptation of monitoring strategies for individual sites, and the utilization of site monitoring resources. SPOT generates user-triggered and automatic actions and pushes those actions back to third-party systems via an API to adapt the monitoring strategy and maximize the value of incumbent tools. It enables the documentation of site performance and the preparation of key activities to perform during the next monitoring visit. Detailed audit trails hold users accountable for actions and reviews, enhancing inspection readiness. By integrating all key data sources into one environment and visualizing the data in easy to interpret dashboards, SPOT enables CRA to more efficiently identify and document key activities to perform during the next monitoring visit. It also provides site performance insights on previous studies, meaning sponsors and CROs can identify successful sites, and replicate their selection and recruitment approaches to better plan for future clinical trials. Importantly, SPOT allows study teams to take timely corrective action, ensuring resources are directed to where they are needed most, and maximizing clinical trial success. 

Credible Planning | PACE v4 | Booth 229  https://www.credibleplanning.com 

Brief Product Description & Technical Specifications: 

The PACE Platform is composed of three interconnected modules that facilitate feasibility and operational teams to standardize trial planning, tracking and management across the lifecycle of their studies

1. Geo-Optimize - To Create / Optimize clinical geostrategies in a consistent data-driven manner, allowing users full control over the use of qualitative or quantitative data to drive decision-making.

2. Pilot - This module supports planning, tracking & reforecasting of clinical studies of any complexity (single or multi-cohort) through an easy-to-use interface. Users can plan study start-up, site activation, and enrolment for all study types with outputs aligned to their internal systems straight from the system at a study/country/site level.

3. Clintelligence - This module acts as a feedback mechanism to help operational teams & specifically leadership to understand planned versus actual performance at a Study/Country/TA level /Portfolio level. This capability is a true game changer for monitoring performance, system usage and or compliance aspects of clinical operations. 

Crucial Data Solutions | TrialKit AI; v7.9 | Booth 729  https://www.crucialdatasolutions.com/ai/ 

Brief Product Description & Technical Specifications: 

TrialKit AI is the first production-ready AI analytics engine seamlessly integrated within an end-to-end eClinical platform. Built to make clinical trial data analysis accessible to all users, TrialKit AI enables researchers, site monitors, and clinicians to uncover actionable insights by simply asking questions in natural language. New in this release: TrialKit AI introduces advanced features like automated daily data trend updates, real-time visualization through sophisticated dashboards, and predictive modeling capabilities that estimate probabilities, confidence rates, and standard errors. These enhancements simplify complex statistical analysis, making it intuitive and actionable for users without requiring advanced technical skills. Key technical specifications include: Natural Language Processing (NLP): Converts user queries into instant, customized data reports. Advanced Data Visualization: Interactive dashboards and charting tools to identify trends at a glance. Real-Time Insights: Automated updates ensure users stay informed about study performance. End-to-End Integration: TrialKit AI is seamlessly embedded within the TrialKit platform, providing unified access to EDC, ePRO/eCOA, eConsent, RTSM, and more. Scalability: Supports studies of all sizes, from small pilot studies to global-scale clinical trials, and performs cross-study analysis across any number of studies. By eliminating technical barriers, TrialKit AI accelerates timelines, improves data accuracy, and enhances decision-making in clinical research. With these groundbreaking features, TrialKit AI sets a new benchmark for accessibility, usability, and efficiency in clinical trial analytics. 

 Cyntegrity | MyRBQM® Portal, V8 | Booth 408  https://cyntegrity.com/microsoft-certified-ai-rbqm/ 

Brief Product Description & Technical Specifications: 

The AI-Augmented Protocol Analysis tool transforms clinical trial risk management by automating the evaluation of protocol components using built-in QbD principles. It categorizes risks, formulates risk statements, and aligns workflows with ICH E6 and E8 standards. Its AI-driven processes automatically generate in-depth risk evaluations, suggest mitigation actions, and link relevant key risk indicators, streamlining traditional risk assessment steps. What sets this tool apart is its certification under Microsoft Healthcare AI standards, making it the first RBQM solution to achieve this recognition. This certification validates the tool’s secure, ethical, and high-performance application of AI in clinical research. Users benefit from early risk detection, improved decision-making, and greater efficiency while maintaining compliance and focusing on trial safety and quality. Launched in Q1 2025, the AI-Augmented Protocol Analysis tool integrates seamlessly into the MyRBQM Portal, enhancing trial consistency and reducing manual effort. This innovation reaffirms Cyntegrity’s commitment to combining AI advancements with ethical practices, ensuring a dependable and transformative impact on clinical research processes. 

Dacima | Survey Module for REMS | Booth 630 https://www.dacimasoftware.com/products/

Brief Product Description & Technical Specifications:

Dacima’s Survery module offers a crucial breakthrough for REMS surveys. The latest iteration introduces transformative capabilities, setting it apart from traditional offerings. It is designed with flexibility, scalability and compliance at its core. Dacima seamlessly manages complex surveys across diverse populations, including patients, healthcare professionals, and pharmacists, while strictly adhering to FDA 21 CFR Part 11 standards. Key innovations include token-based database linking to maintain strict PII separation and a customizable interface for multi-study closure messages under a single URL. These features ensure complete data security and operational efficiency. Advanced survey functionalities, such as randomized question values, image-based data entry, and built-in edit checks, allow users to maintain data quality and accuracy while meeting their diverse requirements. The system’s architecture is purpose-built to meet the most stringent regulatory standards, with modular databases for contact management, survey data, and compensation. This robust design supports seamless integrations, such as BHN Rewards (formerly Rybbon) for participant rewards, and delivers a user-centric experience with automated notifications and eligibility-based participation management. By combining innovation, compliance, and a deep understanding of clinical trial complexities, Dacima distinguishes itself as the go-to choice for organizations seeking reliable, efficient, and secure survey solutions.

Embleema | Embleema ConsentBridge (version 2025.1) | Booth 203  https://www.embleema.com 

Brief Product Description & Technical Specifications: 

Break free from post-trial consent barriers with the Embleema ConsentBridge Platform! This first-of-its-kind solution transforms how sponsors maintain their participant relationships after database lock, without compromising privacy or compliance with 21 CFR Part 11, HIPAA, and GDPR requirements. Our cloud-based platform seamlessly connects three critical components: - Real-time consent management across any trial phase, including post-trial - Secure PII updates that maintain data linkages over time - Dynamic tokenization that preserves participant privacy Through intuitive mobile and web apps, participants directly manage their consents and personal information. Meanwhile, sponsors maintain compliant oversight through our secure dashboard, powered by flexible APIs that integrate with your existing EDC systems. What's New in 2025? - Game-Changing Legacy Trial Support: Closed-trial participants can now self-register and manage consents—finally solving the "frozen EDC" problem. - Multi-Network Tokenization: Generate tokens across multiple data networks to maintain reliable, de-identified data even as participant information changes. - Secure Participant Connection: Our platform serves as the trusted bridge between sponsors and participants, enabling optional data sharing and re-engagement for future research while maintaining privacy barriers. Transform your post-trial participant engagement from a regulatory risk into a strategic advantage with Embleema's comprehensive solution! 

 EmVenio Research, a PCM Trials Company | EmVenio Research Center (ERC) | Booth 1428  http://www.emvenio.com 

Brief Product Description & Technical Specifications: 

EmVenio Research Centers (ERCs) offer comprehensive, full-service capabilities within community-based hospitals and clinics, strategically situated in research-naive locations. This approach expands access to difficult-to-reach populations, enhancing patient recruitment and retention, and ensuring more inclusive and diverse clinical trials. Each of the four centers areis situated affiliated within one of foura Prime Healthcare hospitals or clinics, part of one of the nation’s leading health systems across the US. By integrating within trusted community hospitals, ERCs improve participant comfort and engagement, ultimately leading to more effective and efficient clinical research outcomes. Supported by experienced clinicians and expert Principal Investigators, ERCs provide broader therapeutic area expertise through hospital-affiliated specialists and access to advanced diagnostic procedures and imaging within Prime Healthcare. Due to our centralized infrastructure, participants can tailor their trial visits to their preferences, choosing from on-site research centers within Prime Healthcare hospitals and clinics, mobile Community Research Sites strategically located in adjacent communities, and home visits by Certified Mobile Research Nurses. By leveraging the comprehensive resources of hospital -based centers and the convenience of mobile sites and home visits, EmVenio can conduct more effective and efficient clinical trials, ultimately leading to more robust and representative research outcomes. 

 Everyday Health Group, Pregnancy & Parenting | Patient Recruitment | Booth 121  https://www.ehg-pp.com/ 

Brief Product Description & Technical Specifications: 

Everyday Health Group Pregnancy & Parenting provides recruitment services for women’s health and pediatric clinical trials through our What to Expect and BabyCenter apps and websites. We reach 70% of pregnant women in the US, making our services indispensable for research involving women and young children. Our digital media solutions connect our clients directly with the right audiences. With Gen Z now making up 48% of first-time parents, it’s critical that clinical researchers not only optimize recruitment efforts for diversity but prepare for the next generation. In our newest report, EHG P&P shares the results of surveying 3,500 diverse women to assess their current attitudes, knowledge and behavior around clinical research. Our in-depth insights unveil how Gen Z differs from previous generations and what motivates different cohorts to take action. We leverage our deep understanding of pregnancy and parenting stages to engage parents and soon-to-be moms at their most relevant milestones. Due to the popularity of our trusted brands, we’re able to promote clinical trials to a diverse and engaged audience, significantly improving recruitment outcomes. 

Exostar | Exostar Clinical Trial Access Management (SAM V6.2) | Booth 812  http://www.exostar.com 

Brief Product Description & Technical Specifications: 

The Clinical Trial Access Manager (CTAM) is an integrated solution built on Exostar’s Secure Access Manager (SAM), designed to streamline application access management for clinical trial operations. CTAM centralizes the process for managing user access, application permissions, and compliance tracking across multiple trials and sites, reducing the administrative burden on sponsors and site personnel. CTAM automates user onboarding, role assignments, and provides real-time insights into user access and trial progress. What is new in this release: Real-time dashboards: Provide immediate visibility into onboarding progress, user access, and compliance statuses. Automated subscription workflows: Allow for seamless management of application access and role assignment. Planned integration with Learning Management Systems (LMS) and Clinical Trial Management Systems (CTMS): Future updates will automate training verification and enhance compliance tracking. Role-based access control via Rule Box (planned): Will allow sponsors and site personnel to define policies based on job roles, automating the assignment of access permissions and administrative tasks at the trial and site levels. CTAM offers a streamlined, centralized solution to manage trial access efficiently, improving operational performance, security, and compliance. 

Fortrea | Xcellerate® | Booth 1008 https://bis.fortrea.com/login

Brief Product Description & Technical Specifications:

Risk Radar is the first AI Agent in Fortrea’s AI Agent network, designed to proactively identify and mitigate trial risks. It analyzes protocols, study documentation, and Fortrea’s extensive risk library to streamline risk assessment and enhance decision-making for study teams. This release introduces a powerful AI-driven backend with: Adaptive Retrieval-Augmented Generation – Dynamically retrieves and integrates relevant knowledge for highly accurate risk identification. Agentic AI Frameworks – Enables autonomous decision-making and iterative problem-solving, reducing manual workload. Chain of Thought Reasoning – Generates step-by-step explanations for each detected risk, ensuring transparency. Enhanced Risk Matching – Uses vector embeddings and cosine similarity to precisely align study content with known risks. LLM-Driven Validation – Ensures detected risks are contextually relevant before generating structured outputs. What’s New in This Release? Expanded Risk Detection – Now incorporates insights from Risk Library, study protocols, and supporting documents for higher accuracy. Improved Similarity Matching – More precise vectorization refines how risks are linked to study materials. Automated Risk Justifications – Each identified risk now includes AI-generated reasoning for better context. Seamless API Integration – Returns structured JSON outputs for easy integration into trial workflows. Next Steps: Risk Radar will soon analyze real-time study data, detect early risk trends, and collaborate with other AI Agents—making trial oversight more intelligent, proactive, and efficient.

GlobalData | Sales Intelligence Solution - v1.0 | Booth 131  https://www.globaldata.com/custom-solutions/solutions/sales-intelligence/ 

Brief Product Description & Technical Specifications: 

GlobalData's Sales Intelligence Solution improves sales effectiveness and seller productivity by providing real-time contextual account intelligence, targeted outreach content, and just-in-time life science industry developments. AI is integrated throughout each step of the sales cycle, including AI-powered personalization, natural language search, AI powered slides, and smart sales triggers. Giving sellers the information they need, when they need it, to enable them to have the productive conversations with clinical teams and sponsors. Continuous customer engagement drives sales performance and positions businesses to better understand their sponsors, thus driving business excellence and revenue growth. 

Greenphire | Patient Experience Dataset | Booth 709  https://greenphire.com/patient-experience-dataset/ 

Brief Product Description & Technical Specifications: 

Recognizing the tremendous financial and logistical burdens that are placed on clinical trial participants, over the past 16 years, Greenphire has focused on developing a suite of patient-centered solutions to ease their stress, spanning payment technology, travel and logistics services and a patient mobile app. We have seen an increase in adoption of these types of solutions for years but the challenge of understanding and planning for specific patient costs has remained. “As an industry, we are underperforming in efforts when it comes to participant payments,” (Sponsor pov – DIA landscape analysis) Based on years of experience, thousands of studies supported and millions of participant payments executed, Greenphire has developed an all new, industry first “Patient Experience Dataset”. Our Patient Experience Dataset is the first repository of global patient-level cost insights, broken down by phase, therapeutic area and country. This includes average stipends (where permitted) and reimbursements by categorical expense, travel methods and expenses and more. This dataset delivers a comprehensive, centralized view into the patient journey with a deeper level of insights than we’ve ever had in the industry. The end result? Sponsors and CROs will be able to better understand and quantify the participant burden. As such, they will be empowered to better forecast and budget, predict and drive enrollment, streamline EC & IRB submissions in alignment with clinical trial agreements and (coupled with our existing patient travel and payment offerings), deliver the best possible patient experience. 

 H1 | Global Clinical Identifier (GCI) | Booth 1022  https://h1.co/clinical/ 

Brief Product Description & Technical Specifications: 

H1’s Global Clinical Identifier (GCI) Stream is a comprehensive global reference dataset designed to address fragmented and inconsistent clinical trial data across systems. By providing standardized, hierarchical information on key trial entities—such as principal investigators (PIs), healthcare professionals (HCPs), trial sites, and organizations—GCI serves as a single source of truth. It powers existing trial platforms, such as CTMS, by delivering clean, consistent, and globally integrated reference data, enabling organizations to streamline trial planning, recruitment, and management. GCI includes an extensive dataset of global HCPs and HCOs with clinical trial participation. The dataset provides key metadata, such as PI affiliations, contact details, trial experience, site ownership hierarchies, transaction histories, and accurate address information. These insights allow organizations to clarify complex relationships, evaluate site performance, and uncover hidden affiliations, such as mergers and acquisitions. The reference dataset is initially delivered through a seamless and secure process, then refreshed every 15 days to maintain accuracy and relevance, ensuring effortless integration into your existing platforms. 

Havas Faze | Faze | Booth 613  https://www.havasfaze.com/ 

Brief Product Description & Technical Specifications:  

Faze bring consumer brand levels of creativity and service to connect with patients, caregivers and HCP's around the world to bring clinical trials into everyday conversations. We increase understanding and connect with empathy and story telling. We accelerate patient recruitment into clinical trials by creating messaging that cuts through the noise and makes trials impossible to ignore. 

Image Analysis Group | Dynamika version 7.0 | Booth 1331  https://www.ia-grp.com/ 

Brief Product Description & Technical Specifications: 

DYNAMIKA is a comprehensive, enterprise-scale, cloud-native medical imaging clinical research (iCRO) solution developed by Image Analysis Group (IAG). This proprietary platform manages the end-to-end process of clinical trials, covering image collection from sites, quality review, central reads processing, and generation of reports and data sets. The system features granular user permissions, ensuring that study stakeholders can only access data they are entitled to see. This robust access control enhances data security and compliance with regulatory standards, including 21CFR Part 11, ISO 13485, and SOC 2 Type 1. DYNAMIKA is designed for rapid study configuration, supporting even the most complicated workflows and high volumes of data. Its flexibility allows it to handle various imaging modalities across multiple therapeutic areas, from Phase I to IV clinical trials.s. 

Inspire | Patient Voice AI | Booth 428  https://inspireresearch.com/ 

Brief Product Description & Technical Specifications: 

Patient Voice AI is an advanced AI-driven platform that transforms patient and caregiver conversations into actionable insights for life sciences teams. Built on Inspire’s proprietary dataset of over 12 million authentic, unstructured patient discussions, the platform enables researchers to uncover real-world challenges, unmet needs, and treatment preferences with unprecedented clarity and speed. New in this release: Real-Time Access: Continuous insights from real-world patient discussions, eliminating delays associated with traditional methods. Scalable AI Analysis: Process thousands of patient conversations in minutes, saving time while improving the depth of insights. Validation by Communities: Insights are confirmed by the very patients and caregivers whose data is analyzed, ensuring accuracy and relevance. Technical Specifications: Data Source: Inspire’s disease-specific patient communities, containing over 12 million conversations. AI Framework: Generative AI and natural language processing (NLP) trained specifically on healthcare-related datasets. Core Features: Patient journey mapping. Identification of unmet needs and barriers to treatment. Continuous, scalable analysis of patient-generated content. Integration with claims and EHR data for deeper insights. Output: Actionable insights delivered as dashboards, reports, and customized visualizations. Patient Voice AI sets a new standard for patient-centric decision-making in life sciences, enabling teams to bring therapies to market that truly address patient needs. 

IQVIA Technologies | One Home for Sites Version 2.1 | Booth 808  https://www.iqvia.com/onehome 

Brief Product Description & Technical Specifications: 

One Home as a platform is strikingly simple. Its main feature is the SSO System Library, where site users will find the “tiles” that represent the tech vendors that are SSO-enabled. Clicking on a tile will bring them into the system without additional authentication. More than 100 site personnel have given input in the development of One Home. Additionally, dozens of clinical technology vendors that understand an industry-wide approach is the only way to increase site capacity have engaged with us to map their journey into One Home. We are pleased to have the following tech vendors already available as partners in the platform, with many more coming soon: Medidata, Clario, LabCorp, Signant Health, Greenphire, TruLab, Viedoc, Zelta, Patiro, Praxis, Quipment, and Biofourmis. Additionally, nearly a dozen IQVIA Technologies products are integrated into One Home. Most of these vendors compete with each other, but all have put the needs of sites ahead of any competitive concerns. SCOPE 2024 was instrumental in bringing these vendors together, when we opened up our Partnership Program and hosted many discussions. Since last year’s conference, IQVIA Technologies piloted the Beta version of One Home, released Version 2.0 for free site access in September 2024, and released Version 2.1 for sponsors to license in December 2024. As the only industry-wide solution to site technology overload, we humbly ask for One Home to be voted Best in Show! 

Keiji AI | TrialMind 1.0 | Booth 1040  https://keiji.ai 

Brief Product Description & Technical Specifications: 

TrialMind is a generative AI platform tailored to the clinical trial domain, integrating specialized AI agents for literature mining, trial design, protocol drafting, optimization, and data analysis. Powered by years of AI research, the platform leverages a foundation model, Panacea, fine-tuned with diverse trial protocols and large publication database, ensuring task-specific accuracy. Key features include automated systematic reviews, patient-trial matching, and feasibility analysis, all underpinned by robust data pipelines for high-quality data ingestion and processing. What’s New in This Release: Enhanced Panacea Model: Now supports multi-trial summarization and cross-study insights. Advanced Trial Data Analysis Module: Automated data science code generation. AI-Assisted Drafting: Improved protocol and informed consent form generation with AI drafting agents. On-Prem Deployment: TrialMind can now be integrated into customer environments with privacy-preserving APIs for enhanced security. This release represents a significant leap forward in accelerating clinical trials while maintaining accuracy and reducing costs. 

LexisNexis Risk Solutions | Research-Ready Healthcare Data Blends | Booth 629  https://risk.lexisnexis.com/healthcare/real-world-data 

Brief Product Description & Technical Specifications. Be sure to specify what is new in this release: 

Using referential-based tokenization, these innovative data blends include two or more patient-level datasets (care delivery, mortality, and social determinants of health), for comprehensive, research-ready datasets – standardized, expert determined and ready for immediate use. 

MaxisIT Inc | Site Copilot | Booth 917  https://maxisit.com/ 

Brief Product Description & Technical Specifications: 

Site Copilot is built on Dtect AI, a multi-agent AI, under MaxisIT’s Agentic AI Platform. Site Copilot helps staff in improving compliance, detecting quality issue, applying resolution, and mitigating risks. It enhances connectivity and collaboration between sites and sponsors; acts as a real-time assistant offering actionable insights, and reduces site burden in workflows MaxisIT’s Agentic AI Platform integrates with site-facing technologies, providing unified view across data and documents in clinical research workflows. Site Copilot offers a conversation interface for staff to ask questions, gather insight, and perform actions. DTect AI is a multi-agent app that detects anomalies, recommends actions, and manages quality score by keeping human-in-the-loop. Site Copilot leveraging DTect AI agents – 1. Detects and reports anomalous data, trends, events, risks, actions in the clinical research workflow. 2. Recommends next best action recommendation to rectify such anomaly, mitigate risks and improve outcome by keeping human-in-the-loop. 3. Calculates overall “Quality Score” and “Risk Score” of the site by continuously assessing evolving scenarios on autonomous basis. 4. Drives more accurate and reliable results by reducing the risk of incorrect conclusions and transitioning to hybrid workflows managed by AI and AI-augmented site staff. MaxisIT’s Agentic AI Platform for clinical trials focuses on optimizing outcomes by suggesting the next best action. Available through our platform’s marketplace, these agents can be easily integrated into existing workflow using APIs with user-defined configurations. Each agent or agentic orchestration comes with conversational AI Agent that assist clinical trial teams in accessing insight as well as taking actions. 

Medable | Medable Studio | Booth 717  http://www.medable.com/ 

Brief Product Description & Technical Specifications: 

Medable Studio + AI is a revolutionary platform designed to automate, streamline, and optimize the clinical trial study build process. Integrating cutting-edge generative AI, Studio + AI enables sponsors to design, edit, and deploy eCOAs with unprecedented speed and precision. The platform's reusable content library stores validated instruments and translations for efficient study setup. Medable AI allows users to upload protocols in formats like PDFs, and Medable AI and generate assessment screens and instruments in seconds, refining them through smart prompts. This capability drastically reduces manual effort, enabling builds that previously took days to be completed in minutes. The Studio + AI platform is powered by four key components: eCOA Builder with Medable AI: Automates the creation of assessments and instruments. Smart prompts allow rapid refinement of complex logic and customization at scale. Point-and-Click Schedule of Assessments Builder: Enables users to easily configure and manage visits, time triggers, and dependencies for seamless patient scheduling. Translation Workbench: Centralizes all translation workflows, allowing for real-time edits and updates, and minimizing costly back and forth. Cross-Study Content Library: Stores translated assessments in one place for efficient reuse across studies, accelerating timelines and ensuring consistency. Medable Studio + AI also integrates directly with Medable’s ecosystem, including Total Consent and TeleVisit, creating an all-in-one solution for study configuration and deployment. The platform is versionless, meaning continuous updates and global compliance without the need for revalidation. Real-time collaboration tools further enhance productivity, allowing sponsors to visualize and manage their builds seamlessly, gaining unparalleled efficiency, precision, and control in study build. 

 Medidata | Medidata Clinical Data Studio | Booth 903  https://www.medidata.com/en/clinical-data-studio/ 

Brief Product Description & Technical Specifications: 

Clinical Data Studio, launched in June 2024, is a data source agnostic experience that orchestrates data integration, standardization, reconciliation, and quality management across multiple sources. Designed to simplify the complex data lifecycle by connecting numerous data sources with a streamlined data ingestion and standardization engine, Clinical Data Studio accelerates activities for clinical data management and operations teams by integrating data review and risk management capabilities in a consistent, collaborative user experience. Clinical data managers/scientists, programmers, central monitors, and medical monitors work together on all data in one experience, powered by automation, analytics, and AI, to accelerate data review workflows, mitigate data quality risks, and help ensure patient safety. This solution combines advanced capabilities for data review, medical/safety monitoring, risk management, audit trail review, and centralized statistical monitoring with a no/low-code experience for ingesting, validating, standardizing, and integrating/transforming data from multiple sources. Clinical Data Studio has a positive impact on data quality through powerful capabilities simplified in an intuitive experience: - Streamlined self-service data ingestion agnostic of source - Automated, real-time data review, reconciliation, and surveillance - Risk management and central monitoring - Self-serve dynamic visualizations for real-time safety monitoring - Bulk query management and external data vendor communication connection - Embedded AI and ML capabilities, including anomaly detection, data reconciliation, and data transformation - Flexible Clean Patient Tracker for an ongoing task and data cleanliness progress tracking - Transformation engine for low code data standardization and SDTM dataset creation - Automated mining of audit trail data with generative AI to save time and effort 

Milliman IntelliScript | Irix® Prescription Data, Irix Medical Data, and Irix Rules Engine | Booth 1129  https://www.rxhistories.com/clinical-trials-eligibility/ 

Brief Product Description & Technical Specifications: 

Irix® helps determine a participant’s eligibility in real time at each critical milestone in your clinical trial—from pre-screening through enrollment and ongoing evaluation. It empowers you to enroll the right participants faster, reduce site burden, flag adverse events and protocol deviations, and ensure your trial’s integrity. With basic participant information and a HIPAA authorization, Milliman IntelliScript can instantly return years of interpreted, structured prescription histories and medical claims data on nearly any U.S. individual. 

Nurocor, Inc. | Nurocor Clinical Platform 9.5 | Booth 713  https://nurocor.com/ 

Brief Product Description & Technical Specifications. Be sure to specify what is new in this release: 

Nurocor’s Specimen Management application implements a standards-driven approach for assay definitions. This approach enables sponsors to define assay standards once and leverage those standards to prime study designs with consistent specifications. Once the study team adjusts these standards to align with study-specific requirements, Nurocor Specimen Management generates comprehensive collection plans using a novel “assay-up” approach which supports automated combining of compatible biospecimens. Such an approach both increases efficiency and reduces operational costs and patient burden. Generated plans are actionable and can be used to support automated provisioning of central lab specifications, kit building requirements, site manual specifications and operational specimen tracking systems among others. Specimen Management is a composable component of the microservice architecture based Nurocor Clinical Platform (NCP). Sponsors can choose to implement NCP with a sole focus on biospecimen planning, or as part of a broader suite that encompasses objectives and endpoints, eligibility criteria, interventions and administered products and other protocol design elements. NCP establishes a “single source of truth” for study designs, producing a comprehensive, fine-grained and semantically well-defined design model that can then be leveraged by NCP’s Authoring application to produce template-based study documents such as the study protocol, informed consent forms, lab manuals and many others. In addition, this design model can be extracted from NCP in a technical form to support automated provisioning of operational systems such as data collection, specimen tracking and others. Use of NCP can thereby result in significant savings both in startup costs as well as time to FPFV. 

Phastar | Clinical Intelligence (Data Analytics Platform) Platform | Booth 329  https://phastar.com/solutions/digital-acceleration/ 

Brief Product Description & Technical Specifications: 

The Clinical Intelligence Portal leverages data visualization and analytics to provide near real-time data access. The portal automates data processes and ensures regulatory compliance, offering user-friendly tools for deep data understanding and rapid anomaly resolution. Clinical Intelligence offers a modular approach giving clients the flexibility to select the apps that suit their specific needs and budget, or to acquire the full suite to fully optimize clinical trial processes. Whether clients require tools for visualization, analytics, data management, recruitment forecasting, RBQM, medical monitoring, DMC or more, they can adapt the platform to meet their unique requirements. A new addition to the platform is an RBQM app. The tool supports critical RBQM processes like Risk Assessment, Central Monitoring, Issue Management, Risk Reassessment, Targeted Site Monitoring, and KRI Tracking, while ensuring regulatory compliance and enabling continuous, data-driven improvements throughout the clinical trial. A key feature of RBQM applications is the ability to assign risk scores to different clinical sites or activities based on predefined criteria. These risk scores help prioritize sites that need more attention. Another notable addition is the Recruitment Forecasting app, developed in partnership with Sponsor X to address recruitment challenges. Using advanced statistical modeling, including a Kaplan-Meier model, the app predicts participant progression and treatment administration timelines, accounting for late site openings and real-time data updates. The app allowed Sponsor X to optimize site performance, based on screening duration probabilities, reducing timelines by three weeks and generating significant savings. 

Phesi Inc. | Trial Accelerator™ Platform V2 | Booth 923  http://phesi.com 

 Brief Product Description & Technical Specifications: 

Phesi, the leading patient-centric data science company, has launched Version 2 of its award-winning AI-driven Trial Accelerator™ Platform. With the industry’s largest database of contextualized data from 132 million patients, it enables trial sponsors to identify the highest performing investigator sites, improve enrollment, reduce site and patient burden, and accelerate cycle times. It enables protocol design optimization, eliminating unnecessary amendments, and ensures greater precision, insight and certainty across clinical development. Version 2 highlights: • A unique, extended catalogue of 42 Digital Patient Profiles including the most studied and rare diseases providing detailed patient insights • New self-service Investigator Site Profiling delivering detailed visibility into investigator site expertise and clinical relevance • Enhanced Patient Access Score providing a unique performance measure of an investigator's potential to access the patient population defined in the protocol, aligned to the Digital Patient Profile • New Patient Burden Score analyzing modal design values in related trials for the Schedule of Activities. • Patient Enrollment Rate for predictive scenario modelling of different protocol design criteria • Patient Diversity Score to ensure inclusion and fair representation in clinical trials Trial Accelerator transforms clinical development, profiling patient populations using real-world data, optimizing protocol design, improving investigator site performance and generating digital twins. It leads the way in innovation, supporting the commercialization of drugs including Keytruda and winning Frost & Sullivan’s 2024 Global Enabling Technology Leadership Award for AI-enabled clinical trial design. 

Praxis | Sample, version 1 | Booth 912  http://www.GoPraxis.com 

Brief Product Description & Technical Specifications. Be sure to specify what is new in this release: 

Sample is a brand new offering that Praxis is excited to launch at SCOPE 2025. This opt-in consumer panel includes patient and caregivers across 25 different therapeutic areas. Through online surveys, digital/in-person focus groups, and in-depth interviews, panelists share valuable feedback while earning reward points in recognition of their participation. To guarantee the highest quality data, every respondent undergoes an exhaustive quality control process, resulting in genuine and reliable insights. To ensure absolute data security, all survey data is hosted on an airtight cloud server with end-to-end encryption and stringent access restrictions. A dedicated in-house team of HIPAA-certified analysts oversees our data privacy measures, ensuring that any personal information shared by panelists remains strictly confidential. Research is analyzed using aggregated data to identify group-level trends while protecting individual privacy. Anonymized or paraphrased quotes are used only with respondents’ consent, and all details are outlined transparently in our privacy policy. In October 2024, Praxis proudly achieved ISO 27001:2022 certification. This milestone underscores our commitment to data security and privacy, especially as we expand our primary research scope. 

 Replior | Replior Smart Scratch Sensor version 1.0 | Booth 202  https://www.replior.com 

Brief Product Description & Technical Specifications: 

Replior’s Smart Scratch Ring, unveiled at Scope 2025, is a next-generation wearable sensor for objective measurement of itch-related scratching in dermatology trials. With a proprietary sensor array designed to detect micro-movements at the fingertips, it captures the intensity, frequency, duration, pressure, and location of scratching events in real time. The ring’s robust battery can last up to a week, so there’s minimal disruption to participants’ routines. The device also tracks vital signs such as heart rate, blood oxygen, and skin temperature, providing a holistic view of patient wellbeing. Skin temperature gives great patient compliance insights for wearing the device or not. We also capture exposure to visible light (Red, Green, Blue channels) providing knowledge to the patients surrounding environment. Data is transmitted securely to our platform, which supports seamless integration. As a first-of-its-kind finger-worn solution, the Smart Scratch Ring brings a deep understanding together with the traditionall patient reported outcomes, by delivering continuous, actionable data. By replacing guesswork with real-time insights, sponsors gain faster, more accurate endpoints and reduce patient burden. With advanced analytics, the ring can generate heatmaps illustrating body areas most affected by scratching. Our mission is to empower clinical researchers with data-driven clarity, and the Smart Scratch Ring marks a new era in wearable technology for dermatological studies. 

Saama| DocGenAI | Booth 1009  http://www.saama.com 

Brief Product Description & Technical Specifications. Be sure to specify what is new in this release: 

DocGenAI is a state-of-the-art framework that leverages advanced artificial intelligence (AI) to streamline the creation and management of clinical documents. With pre-loaded templates, generative AI-driven content creation, and customizable workflows, DocGenAI accelerates document timelines, improves quality, and reduces manual effort. This AI-powered solution empowers teams to create accurate, compliant documents efficiently and at scale, transforming the clinical trial documentation process. 

ScienceMedia | SMi Engage (Version 1) | Booth 1312  https://sciencemedia.com 

Brief Product Description & Technical Specifications: 

SMi Engage is a cutting-edge, cloud-based video solution designed to streamline clinical trial education through engaging, participant-friendly training. Powered by MindFlow, a research-backed Cognitive Theory of Multimodal Learning, SMi Engage delivers bite-sized, need-to-know content that enhances long-term retention. By combining small, specific bursts of information with a methodology that maximizes comprehension and recall, SMi Engage empowers participants to learn what they need, when they need it, fostering better understanding and engagement.

Key features include its flexible branding customization options that allow clinical trial sponsors to tailor the solution to align with their unique identity and participant needs.

All content has the add-on ability to be professionally translated and culturally tailored, supporting representative populations through patient-focused education. Its animated, interactive video modules are accessible on both desktop and mobile, allowing participants to train conveniently from anywhere.

Designed to simplify the complexities of clinical trials, SMi Engage combines innovative technology and evidence-based learning strategies to accelerate recruitment, improve informed consent processes, and strengthen participant retention—all while meeting FDA diversity guidelines with patient-focused, accessible education.

 SiteCentric | SiteCentric CTMS | Booth 313 https://sitecentric.us/

Brief Product Description & Technical Specifications:

SiteCentric is an All-in-One Clinical Trials Management and Communication Platform built by sites, for sites. Including:

* CTMS * Regulatory & eISF * eSource * Patient Text Messaging * Remote Visits * Study Performance Metrics * Community Partners * Dashboards * Study Portal Access Manager * Patient Recruiting/Advertising * SMS Recruitment * Study Pipeline Management * Finance and Projections * External Provider Cost Management * Advertising ROI Metrics * Payment Reconciliations and Invoicing * Internal Quality Assurance * Patient Reimbursement (Stipends) * Patient Satisfaction Monitoring * Remote Monitoring * Custom Integrations with industry-leaders * Website Appointment Form SiteCentric CTMS+ platform was built to address needs of a major US-based multi-specialty clinical research site network. It was built from over 25 years of experience in running clinical trials.

Scout | Scout Coordinator | Booth 1308  https://www.scoutclinical.com/scout-for-sites 

Brief Product Description & Technical Specifications: 

New for 2024, the Scout Coordinator service is designed to simplify patient support processes for high-volume clinical sites, empowering their teams to focus on core responsibilities in patient care and research. Building upon Scout’s acclaimed Patient Liaison model, this upgraded service introduces a key new feature—Scout will work directly with patients through the Scout Portal on behalf of these busy sites. With this enhancement, site personnel need only complete a quick intake form in the Portal to transfer administrative responsibility entirely to Scout. From that point, Scout handles all patient-facing tasks, including scheduling, reimbursement coordination, travel logistics, and itinerary management. This streamlined process eases the operational load on site staff, enabling them to focus on their priorities while ensuring that patients still receive seamless support throughout their study participation. Beyond reducing administrative burden, the Scout Coordinator service supports protocol adherence by ensuring smooth and timely patient engagement. By managing the complexities of travel and reimbursement logistics, the service helps sites maintain compliance with study requirements while enhancing overall patient satisfaction and retention. This is true innovation in service. The Scout Coordinator program acts as an extension of site teams, offering a tailored, easy-to-use solution that maximizes operational efficiency and contributes to the success of clinical trials. 

Signant Health | Signant SmartSignals® CDR System®, Study Manager V1.4.0 | Booth 1013  https://signanthealth.com/solutions/cdr-system 

Brief Product Description & Technical Specifications: 

The CDR System is a comprehensive cognitive assessment platform, now available as a web-based solution. Built on 40 years of scientific validation and the industry's largest normative database, this latest release maintains the system's gold-standard measurement capabilities while introducing modern accessibility features.

Key Features:

• Browser-based administration, requiring only standard keyboard input

• Millisecond-precision reaction time measurements

• Validated across multiple therapeutic areas and patient populations

• Available in multiple languages (more than 50)

Real-time data capture Core assessment battery:

• Attention

• Information processing

• Working memory

• Episodic Memory

Executive function New in this release:

• Web-based delivery eliminating hardware dependencies

• Left/right arrow key response system replacing traditional button box

• Test-by-test data capture

• Local browser running to avoid impact of poor internet

• Simplified site implementation and communication

Streamlined participant experience Technical:

• Modern web browser

• Standard keyboard

• Stable internet connection

• Data encryption: AES-256

• HIPAA/GDPR compliant

• 21 CFR Part 11 compatible Implementation options:

• Cloud-hosted SaaS

• Enterprise deployment This release maintains all FDA-accepted testing protocols while significantly reducing implementation complexity and increasing global accessibility. 

Sitero | Mentor Accelerate | Booth 209  https://sitero.com/ 

Brief Product Description & Technical Specifications: 

Mentor Accelerate revolutionizes clinical trial operations by seamlessly integrating RTSM, eConsent, and EDC systems into a cohesive platform. Designed to simplify workflows, it enables touchless data exchange while ensuring data accuracy and regulatory compliance. By centralizing operations in the EDC, site users no longer need to navigate multiple platforms, enhancing efficiency and reducing operational silos. Key features include real-time bi-directional synchronization between EDC and RTSM, ensuring accurate randomization data and drug supply tracking without manual intervention. Automated consent and reconsent date integration align with regulatory standards, while site users can manage these processes effortlessly from within the EDC. Mentor Accelerate also supports freezing drug shipments to preserve supply based on trial needs, minimizing waste and maximizing efficiency. New enhancements in this release include upgraded reporting capabilities, providing actionable insights at a glance, and UI updates tailored to improve site satisfaction. These features empower site users and sponsors with real-time data access, improved monitoring, and advanced reporting tools to accelerate trial timelines and ensure high-quality outcomes. With its integration-first design, Mentor Accelerate eliminates fragmented workflows, reduces the risk of errors, and streamlines critical trial operations. By unifying data and processes into a single, user-friendly framework, Mentor Accelerate drives efficiency, improves satisfaction, and ultimately helps sponsors deliver life-saving treatments faster. 

Slope | Biospecimen360™ | Booth 1216  https://www.slopeclinical.com/software 

Brief Product Description & Technical Specifications: 

Slope’s vendor-agnostic software, Biospecimen360™, streamlines and automates the biospecimen lifecycle with seamless integrations across labs, EDC systems, and kitters. It offers end-to-end sample management and inventory tracking — including precise auto-resupply for lab kits, and a traceable chain of custody for samples. Digitized workflows guide site users from sample collection through shipment, with software-enforced guardrails and alerts to ensure compliance. Features like streamlined metadata capture, automatic data sharing, and a data insights dashboard minimize reconciliation needs, accelerate data access, and empower data-driven decision-making for sponsors. In Q4 2024, Biospecimen360™ introduced the bi-directional API integration with LabConnect’s Laboratory Information Management System (LIMS), marking an historic industry-first for driving sample data continuity from collection at the sites to a lab. This real-time integration enables bidirectional data exchange, including sample and subject metadata, kit and bulk supply inventory control, and data-driven kit reordering. Key advancements achieved with this integration include: Elimination of common accessioning errors tied to paper requisitions Removal of discrepancies from duplicative data entry Eradication of data entry delays typical with lab-specific e-requisitions Full control over kit inventory, sample metadata, and shipping This integration sets a new industry standard for real-time data exchange, delivering unparalleled data integrity. It addresses critical gaps in biospecimen lifecycle management by tackling data quality and standardization challenges, providing a comprehensive solution for the evolving needs of modern clinical research. 

StudyKIK, a Syneos Health Company | Patient Companion App | Booth 909  https://studykik.com 

Brief Product Description & Technical Specifications: 

Patients often ask themselves: Did I take my dose today? How do I prepare for my next visit? With the patient companion app, answers are just a tap away. Configurable for any therapeutic area, the patient companion app centralizes all study-related tasks into one easy-to-use platform. Patients can receive appointment reminders, participate in telecare visits, log medication doses, manage their reimbursements, and stay in direct contact with their site. Real-time data syncs back to the site, enabling remote monitoring of patient compliance and improving site efficiency. This connected approach reduces the need for frequent on-site visits, enhances oversight, and helps ensure patients stay on track. By reducing administrative burden and offering more oversight, the app helps keep patients on track and engaged, improving retention and making the trial journey easier for patients and site teams alike. 

Synterex, Inc. | AgileWriter, v2.1 | Booth 112  https://www.synterex.com 

Brief Product Description & Technical Specifications: 

AgileWriter.ai is an AI-powered platform developed by Synterex that helps medical writers create, redact, format, and manage clinical trial documents for regulatory submissions. It has undergone continuous development since its first release in October 2023. At its launch, AgileWriter (v1.0) had the ability to generate high-quality, compliant plain language summaries, plain language synopses, and informed consent forms. These patient-facing documents meet readability and health literacy requirements so that trial participants can understand the research and make informed decisions before entering a trial. Currently at v2.1, AgileWriter has additional functional capabilities including publishing and redaction of documents, clinical study reports, safety narratives, and module document generation, with an interface for reviewing and editing documents. This tool allows for a significant reduction of manual effort and acceleration of the document development lifecycle, all while maintaining a human-in-the-loop methodology to ensure proper human oversight of the process. It has an intuitive and user-friendly interface that adheres to the W3C® Authoring Tool Accessibility Guidelines (ATAG) guidelines, maximizing the intersection between technology and accessibility. AgileWriter is built on well-known technologies to allow for scalability and seamless integration into existing workflows and follows cybersecurity best practices to prioritize data security, with client file storage and access following Microsoft provisioning techniques. 

Tasso, Inc. | Tasso Mini & Tile-T20 | Booth 1029  http://www.tassoinc.com/tasso-mini, http://www.tassoinc.com/dried-blood 

Brief Product Description & Technical Specifications: 

Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, will be showcasing its latest patient-centric collection systems at SCOPE. Tasso’s proprietary technology collects clinical grade blood samples with a virtually painless, patient-preferred process. The new Tasso™ Mini device solves the challenge of frequent blood sample timepoints with a gentler collection experience, ideal for sensitive populations or repeat sampling. Tasso Mini is compatible with standard Microtainer tubes or can be used with Tasso’s next-generation precision dried blood spot cartridge. 

 Trial By Fire Solutions, LLC | SimpleTrials CTMS/eTMF | Booth 431  https://www.simpletrials.com/ 

Brief Product Description & Technical Specifications:   

SimpleTrials is a leading on-demand subscription-based Clinical Trial Management System (CTMS) and electronic Trial Master File (eTMF) designed for small to mid-sized clinical research organizations. It combines affordability with robust functionality to streamline trial operations, improve compliance, and optimize workflows. SimpleTrials offers scalability for organizations managing a single study or a complex portfolio of clinical trials, empowering teams to manage studies with ease and efficiency. The platform is built with user-centric design, providing an intuitive interface and flexible configuration options. It supports end-to-end trial management, including study planning, site management, subject tracking, document management, and reporting. SimpleTrials simplifies onboarding with guided setup and expert support, ensuring quick adoption and operational readiness. Technical Specifications and Features Study Management: Centralized dashboard for planning and tracking study milestones, budgets, and timelines. Site and Subject Management: Tools for site selection, enrollment tracking, and site performance metrics. eTMF Capabilities: Fully integrated document management system for real-time collaboration, audit readiness, and compliance with industry standards like ICH GCP and 21 CFR Part 11. Reporting and Analytics: Pre-built and customizable reports for data-driven decision-making. User Access Controls: Role-based permissions to ensure data security and compliance. Integration Ready: API support for seamless integration with EDC, eConsent, and other clinical tools. Cloud-Based Platform: Secure, web-based access with no additional IT infrastructure required. SimpleTrials delivers a cost-effective, comprehensive solution to help clinical research teams achieve success while staying within budget. version 6.7.106 

Trialbee | Trialbee Honey™ | Booth 1116  https://trialbee.com/recruitment-solutions/honey-platform/ 

Brief Product Description & Technical Specifications: 

Over the past year, Trialbee Honey™ has made significant strides in advancing patient recruitment, solidifying its position as the leading, vendor-agnostic patient recruitment platform (PRP). Our platform continues to innovate with a range of enhancements designed to streamline the recruitment journey from initial interest to enrollment. Here’s a look at some of the key advancements we’ve made: Sponsor-Specific Patient Registry This year, we introduced a major upgrade to our patient registry—a dynamic, sponsor-specific database that goes beyond traditional registries. Managed directly within the Trialbee Honey platform, it provides a pool of patients who have actively expressed interest in a sponsor’s studies. By integrating targeted email and SMS communication with this registry, sponsors can maintain a steady and personalized line of communication, keeping patients engaged and ready for enrollment. This innovation not only reduces recruitment costs but also improves enrollment success by ensuring the patient pool stays active and informed for future trials. Enhanced Site Workflows Trialbee Honey has also made major improvements to site workflows. Now, sites can seamlessly manage both pre-screening and enrollment in a single, unified platform. This enhancement simplifies processes by providing the necessary communication tools and pre-qualifying information sites need, enabling them to focus on what matters most: caring for patients. With this upgrade, sites can streamline workflows, reducing time spent on administrative tasks and accelerating trial recruitment. Improved Insights Modules for ROI To help sponsors assess and improve their recruitment strategies, we’ve enhanced our reporting capabilities. The upgraded insights modules allow sponsors to evaluate the performance and ROI of sites, campaigns, and vendors in real time. This data-driven approach enables sponsors to take targeted actions, fine-tuning their efforts and continually optimizing recruitment outcomes. These advancements reflect our ongoing commitment to delivering a seamless, efficient, and data-driven platform that drives better patient recruitment outcomes and supports clinical trials in reaching their full potential. 

TruTechnologies | TruScreen | Booth 940  https://www.trutechnologies.io/truscreen 

Brief Product Description & Technical Specifications: 

Product Description TruScreen is a proactive system for optimizing the screening and enrollment phase of clinical trials. Designed to streamline recruitment efforts, it provides real-time site-level insights, automated alerts, and customizable dashboards that empower sponsors to intervene proactively and improve site performance. By monitoring activity-level progress for individuals throughout the screening process, TruScreen ensures inclusion/exclusion (I/E) criteria issues are caught and addressed before they escalate. This capability helps streamline workflows, reduce delays, and minimize administrative errors, ensuring trials begin on time and on budget while enhancing the experience for both site staff and patients. Technical Specifications Real-Time Monitoring: Tracks site recruitment metrics and activity-level progress for individuals, providing actionable insights. Proactive Alerts: Notifies sponsors and sites of enrollment risks or deviations, enabling timely course corrections. Customizable Dashboards: Visualizes key metrics and site performance in an intuitive, user-friendly format. Guided Workflows: Offers step-by-step guidance to simplify complex protocol requirements during screening. Scalability: Accommodates studies of all sizes, from single-site trials to large-scale, multi-site operations. TruScreen revolutionizes how sponsors and sites navigate the screening phase, delivering a robust solution to one of the most persistent and costly challenges in clinical trials. 

Truveta | Truveta Data | Booth 1220  https://www.truveta.com/ 

Brief Product Description & Technical Specifications: 

Updated daily for the most current view of patient care, Truveta Data provides a complete view of the patient journey, including more than 5 billion clinical notes, nearly 100 million medical images, and billions of linked claims, including closed claims for nearly 200 million patients. Using the Truveta Language Model, a large-language, multi-modal AI model, to ingest, clean, and normalize billions of daily EHR data points for research, Truveta Data is carefully de-identified with the highest security and privacy protection standards. Truveta enables researchers to accelerate the adoption of new therapies and advance patient care with solutions for HEOR, safety, and clinical trials. Truveta Data is the most complete, timely, and clean EHR data paired with SDOH, mortality, and claims data for a complete view of the patient journey. Truveta receives all clinical notes generated during a patient’s care, including progress notes, nursing evaluations, procedure/operative reports, referral notes, discharge summaries, and more. Truveta Data also includes medical images across all modalities, including MRI, CT, X-ray, ultrasound, mammogram, PET, and nuclear medicine, searchable by modality and protocol. The clinical depth of this data enables researchers to have access to the use of highly specific inclusion/exclusion criteria. Aligned with FDA guidance, Truveta established rigorous standards of data quality and provenance and audit-ready processes, procedures, and controls to support organizations in meeting the most stringent regulatory requirements. Truveta Data generates real-world evidence helping accelerate therapy approval and adoption. 

 Univo IRB| OneVerse Version 2.00 | Booth 309  https://www.myoneverse.com/ 

Brief Product Description & Technical Specifications: 

OneVerseTM is a modern, cloud-based IRB platform designed to streamline and simplify the submission and review process. Purpose-built with the latest technologies, it minimizes technical debt while maximizing efficiency and user experience. The platform offers centralized tracking, role-specific views, and dynamically generated workflows tailored to specific submission types. Users benefit from actionable updates via comprehensive dashboards and receive instant support through a groundbreaking live chat feature. By remembering details across documents and studies, OneVerse reduces repetitive tasks and enhances productivity. For IRB reviewers, OneVerse provides tools to access submission history, guidance, and analytics, enabling dynamic, context-specific review form generation. This functionality accelerates determinations and ensures accuracy. Reporting and documentation tools grant study teams access to essential records, amendments, and post-approval support. The system's part 11 compliance and integrated e-signatures eliminate the need for printing and scanning, further improving efficiency. Dynamic and flexible study team management offers visibility and transparency, allowing collaboration across study sites of any size. The platform’s collaborative features enable multiple team members to contribute to submissions even before a draft is finalized, fostering teamwork and consistency. Combining intuitive design, robust functionality, and compliance with regulatory requirements, OneVerse addresses common pain points in the IRB process, making submissions faster, clearer, and more effective. 

Veeva Systems| Veeva eCOA | Booth 916  https://www.veeva.com/products/veeva-ecoa/ 

Brief Product Description & Technical Specifications: 

Veeva eCOA allows biopharmas to build studies faster using a centrally-controlled library of pre-validated and fully reusable eCOAs. On-demand workflows, dashboards, and data exports increase study efficiency and control. The improvements help teams streamline study management while allowing sites to easily navigate workflows that can automate tasks, eliminate duplicate data entry, and simplify device management. Companies can now build eCOA in under four weeks. With more than 180 pre-validated and fully reusable instruments and self-service eCOA study management, study teams can make mid-study changes quickly and access data extracts on demand. All this is possible without an additional cost. 

Veridix AI | Protocol Authoring Co-Pilot | Booth 720 https://veridixai.com/

Brief Product Description & Technical Specifications: 

Veridix AI’s Protocol Authoring Co-Pilot transforms protocol development by streamlining the traditionally labor-intensive medical writing process. Using advanced prompt chaining and a multi-agent Generative AI approach, the co-pilot is reducing protocol authoring times by over 40% in studies we support as a CRO, enabling teams to progress from first draft to final versions with greater speed and precision. The process begins with selecting a protocol template, either an industry-standard format or a client-specific one. Users upload reference materials—such as the synopsis, investigator’s brochure, past protocols, and relevant literature—into a study-specific knowledge base, which prepares these documents for LLM-based querying. The co-pilot’s initial GenAI ‘authoring agent’ drafts the protocol by synthesizing inputs, extracting study-specific context, and auto-generating protocol sections. Advanced prompt chaining ensures the content includes the appropriate level of detail, while automatic referencing guarantees traceability and transparency. A GenAI ‘reviewer agent’ then evaluates the draft for accuracy and alignment across sections, addressing issues automatically where possible and flagging others for user input. Through a human-in-the-loop process, medical writers and stakeholders refine drafts efficiently, providing feedback and making changes directly or via instructions to the ‘authoring agent’. By reducing timelines, ensuring consistency, and enhancing document quality, this Generative AI solution addresses the complexities of clinical trial protocol authoring. It empowers teams to accelerate trial initiation, supporting faster, more efficient clinical research and improved patient outcomes.

VIDA | VIDA Intelligence Platform | Booth 321  https://vidalung.ai 

Brief Product Description & Technical Specifications: 

The VIDA Intelligence Platform enables sponsors to collect and leverage high quality imaging data throughout the drug development and approval process, making AI-powered quantitative imaging scalable for any trial. The platform orchestrates all aspects of clinical trial imaging, including site training, data acquisition, scanner calibration, data exchange and much more. Sites have immediate access to clinical and technical support from VIDA and receive immediate AI-powered feedback on data quality. The platform facilitates the collection and management of a sponsor Digital Biobank. A digital biobank is analogous to a traditional tissue/blood biobank, but for digital patient information over time, including imaging data, test results, demographics, diagnoses, and much more. These digital biobanks allow sponsors to leverage their rich imaging data for years, providing ongoing research value, external control arms, and more. 

Voiant | Voiant Hub 2.0 | Booth 730  https://www.voiantclinical.com/ 

Brief Product Description & Technical Specifications: 

Voiant Hub 2.0 is the second release of the industry-leading imaging platform. Voiant’s fully configurable, AI-powered highly scalable platform can be accessed anywhere, on any device, enabling sites, readers and sponsors to work together within the same platform supporting the entire clinical imaging endpoint data delivery from images upload to queries management, data analysis, and reporting. 

WCG Clinical | WCG ClinSphere™ Total Enrollment | Booth 803  https://www.wcgclinical.com 

Brief Product Description & Technical Specifications: 

WCG ClinSphere™ Total Enrollment is a SaaS solution designed to optimize participant recruitment and retention in clinical trials. Built on WCG’s proven methodology, Total Enrollment offers study and site teams real-time visibility into the participant journey – from enrollment to referrals to retention. The technology empowers users with self-service tools to manage recruitment campaigns, pre-screen participants, and track retention milestones, all while maintaining comprehensive reporting and data integrity. Features: Self-service: Intuitive interface for effortless setup and study management. Configurable pre-screening tools: Tailored forms to improve participant qualification and reduce dropouts. Real-time insights: Enrollment and retention timeline projections, with actionable data to monitor study and participant progress. Built for sites: Ease of use adapting to any site workflow while capturing standardized information. Referral management: Tracks participant sources and streamlines multi-channel recruitment. Retention tracking: Automated scheduling, visit reminders, and real-time updates for participant follow-ups. Technical specs: HIPAA and GDPR compliant, with a secure tenant-based data environment. Milestone tracking for the entire participant journey, configurable per study. Batch upload capabilities for rapid participant data integration. Fully scalable across study size, complexity, and countries. 

YPrime (Y-Prime, LLC)| YPrime Electronic Clinical Outcome Assessment | Booth 603  https://www.yprime.com/ecoa/ 

Brief Product Description & Technical Specifications: 

YPrime's Automated Data Change Form (DCF), newly released in January 2025, revolutionizes clinical trial data management, empowering site staff to execute modifications in minutes instead of days. This innovative solution streamlines workflows, maintains data integrity, and ensures compliance through advanced validation and comprehensive audit trails. By dramatically reducing manual interventions and processing time from an average of 39.6 hours to mere minutes, the DCF tool allows site staff to focus more on patient care and less on administrative tasks. This efficiency not only minimizes errors but also significantly improves overall trial quality and patient experience. With YPrime's Automated DCF Tool: • Users access an easy-to-use interface for all data points, enabling quick value update requests. • Site staff can view current values and request updates, with approval levels varying by data type. • Changes can be made without configuring approvals, eliminating delays for minor modifications. • Site users maintain full autonomy over their data, with automatic API-driven changes and comprehensive audit trails. • Stakeholders can easily view reports of all data changes within a study. • Email notifications alert users to pending DCFs in their queue for review, approval, or confirmation. • All changes are directly made in the study database, automatically syncing to devices, reports, and calculated values system-wide. 

Yunu | Yunu Platform | Booth 106  https://www.yunu.io 

Brief Product Description & Technical Specifications: 

The latest release of Yunu's cloud-based platform offers trial data transparency with real-time results dashboards, guard-railed imaging assessment tools for error-proof, fully-compliant trial imaging data, and the flexibility to leverage on-site readers or extend reads to a global network of specialty readers already connected in the platform. Yunu also now offers integration to Veeva CDB, Florence Healthcare solutions, and IgniteData.